ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Q2 2025 CRO Activity and Intel Report Featuring ICON, AstraZeneca, Akesobio, CSPPC Pharmaceutical, ImmunityBio, Boryung - ResearchAndMarkets.com

The "Q2 2025 CRO Activity and Intel Report" has been added to ResearchAndMarkets.com's offering.

This report offers an in-depth analysis of the contract research organization (CRO) industry, categorized by geography, therapeutic area, and phase of development for Q2 2025.

Reasons to Buy

  • What are the trends by region, therapy area, sites by CROs for the past quarter?
  • Who was the most active CRO in the past quarter?
  • Who were the most active sponsors by market cap in the past quarter?
  • What was the most widely studied therapy area in the past quarter vs. the previous year's quarter?
  • By region, who had the most clinical trials initiated in the past quarter?
  • By region, what were the past quarter's CRO invitations and appointments?

Key Topics Covered:

Introduction

Global

  • CRO and sponsor activity in Q2 2025
  • Most-used CROs
  • Most active large- and mega-cap sponsors
  • Most active mid-cap sponsors
  • Most active small-cap sponsors
  • Clinical trials in oncology and CNS
  • Therapeutic area breakdown of clinical trials initiated in Q2 2025 vs. Q2 2024
  • Trials initiated in the 10 most active oncology indications in Q2 2025 vs. Q2 2024
  • Trials initiated in the 10 most active CNS indications in Q2 2025 vs. Q2 2024
  • Top 10 CROs by number of sites in Q2 2025

North America

  • Clinical trial activity in North America in Q2 2025
  • Most active North American regions in Q2 2025 vs. Q2 2024
  • Phase breakdown of trials initiated in North America in Q2 2025 vs. Q2 2024
  • Therapeutic area breakdown of clinical trials initiated in North America in Q2 2025 vs. Q2 2024
  • Top 10 trial sites by trials initiated in North America in Q2 2025
  • Insights: CRO invites for sponsors based in North America

Europe

  • Clinical trial activity in Europe in Q2 2025
  • Most active European regions in Q2 2025 vs. Q2 2024
  • Phase breakdown of trials initiated in Europe in Q2 2025 vs. Q2 2024
  • Therapeutic area breakdown of clinical trials initiated in Europe in Q2 2025 vs. Q2 2024
  • Top 10 trial sites by trials initiated in Europe in Q2 2025
  • Insights: CRO invites for sponsors based in Europe

Rest of the world

  • Clinical trial activity in ROW in Q2 2025
  • Most active regions in ROW in Q2 2025 vs. Q2 2024
  • Phase breakdown of trials initiated in ROW in Q2 2025 vs. Q2 2024
  • Therapeutic area breakdown of clinical trials initiated in ROW in Q2 2025 vs. Q2 2024
  • Top 10 trial sites by trials initiated in ROW in Q2 2025
  • Insights: CRO invites for sponsors based in ROW

Companies Featured

  • ICON
  • Astrazeneca
  • Akesobio
  • CSPPC Pharmaceutical
  • ImmunityBio
  • Boryung

For more information about this report visit https://www.researchandmarkets.com/r/g63hkc

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.